Business Model and Strategy - The company reported a shift from a single pharmaceutical manufacturing business to a dual-driven "big health" industry model, focusing on both medical services and pharmaceutical manufacturing [22]. - The company has developed a dual-driven strategy in the healthcare industry, focusing on both medical services and pharmaceutical manufacturing [38]. - The company aims to enhance its healthcare services and pharmaceutical R&D, focusing on major chronic diseases and high-end maternal and child health services [98]. - The company plans to implement a dual-driven strategy in 2019, balancing basic and non-basic healthcare services while exploring new high-end health services [99]. - The company is focused on enhancing its drug development capabilities and improving the quality of generic drugs [98]. - The company is committed to improving its operational management and resource allocation to strengthen its market position [101]. - The company recognizes the growing demand for diversified and personalized healthcare services due to urbanization and an aging population [98]. - The company will leverage its hospital network to create a comprehensive health management system covering all life stages [101]. - The company is focused on technological innovation in the medical and pharmaceutical sectors, aiming to build a translational medicine platform and enhance its capabilities in medical data resources [103]. Financial Performance - The company's operating revenue for 2018 was ¥3,838,392,197.48, representing a 12.92% increase compared to the previous year [6]. - The net profit attributable to shareholders was -¥1,417,817,723.30, a decrease of 799.09% year-on-year [6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,395,854,132.33, a decline of 826.17% compared to the previous year [6]. - The total profit for the year was CNY -1,333.91 million, a year-on-year decrease of 536.19% [61]. - The company reported a net loss of approximately ¥1.42 billion for 2018, compared to a net profit of ¥202.81 million in 2017 [117]. - The company reported a significant increase in cash flow from operating activities in the second quarter, amounting to ¥203,061,444.52 [29]. - The company reported a net loss of ¥1,388,000,000 in 2018, with a significant difference from the net cash flow from operating activities of ¥522,565,203.01, primarily due to non-operating cash factors [82]. - The company has committed to transparency and accuracy in its financial disclosures, taking legal responsibility for any misstatements [129]. Investment and Dividends - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [7]. - The company did not distribute any cash dividends for the years 2016, 2017, and 2018, citing significant funding needs for acquisitions and projects [113][118]. - The cash dividend policy has been clearly defined, with no cash dividends or stock bonuses proposed for the past three years [114]. - The company plans to retain all earnings for future investments and operational needs, reflecting a focus on growth rather than immediate shareholder returns [113][118]. - The company has established a three-year shareholder return plan, prioritizing cash dividends over stock dividends to ensure reasonable returns for investors [111]. Operational and Market Expansion - The company operates a total of 1 tertiary hospital, 7 secondary or higher comprehensive hospitals, and 5 hospitals under construction, indicating ongoing expansion in medical services [38]. - The company operates 15 hospitals with 8,700 open beds, serving over 3.5 million outpatient visits and 260,000 inpatient discharges annually, leveraging significant clinical resources for healthcare services [44]. - The company expanded its market presence by adding 3,500 new retail pharmacies and 800 user hospitals during the reporting period [61]. - The company is focused on expanding its market presence through strategic partnerships with healthcare institutions [176]. Risk Management - The company has detailed potential risks in its report, advising investors to maintain sufficient risk awareness [7]. - The company has identified potential risks, including policy changes in the healthcare sector, which may impact its operations and will take measures to mitigate these risks [107]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and senior management [5]. - The company’s independent directors have fulfilled their responsibilities, ensuring proper governance and protection of minority shareholders' rights [112]. - The company has a long-term commitment to transparency in its financial reporting and adherence to corporate governance standards [112]. - The company has committed to avoiding any competition with its controlling shareholder and related parties, ensuring alignment of interests [122]. Social Responsibility and Community Engagement - The company invested approximately 1,027.26 million in poverty alleviation efforts, with health-related poverty alleviation accounting for about 688.57 million [192]. - The company provided medical fee reductions of 113.11 million as part of its poverty alleviation initiatives, benefiting over 1,400 impoverished individuals [192]. - The company has focused on enhancing medical service quality and expanding its healthcare capabilities, contributing to both economic and social benefits [189]. - The company is committed to continuing its precise poverty alleviation plans in 2019, focusing on industrial and health poverty alleviation [197]. Legal and Compliance Issues - The lawsuit involving Pengsheng Heavy Industry and the Xuyi Hospital has a disputed amount of CNY 2.5 million, with the first-instance judgment already in effect [149]. - The performance commitment dispute case has a total performance shortfall of CNY 91.0349 million for the year 2017, with the defendant required to bear joint liability for the debt [152]. - The company is currently negotiating the payment of CNY 25.4765 million for equity transfer price, CNY 1.2 million for legal fees, and penalty fees as per the first-instance judgment [152]. - The first-instance court ruled that the Lan'ao County First Hospital must repay a loan of CNY 1.07813 million, with the case currently under appeal [152]. Environmental Compliance - The company has actively engaged in environmental protection, ensuring all facilities operate within regulatory standards [190]. - The company has complied with various environmental protection laws and has not faced penalties for violations during the reporting period [198].

Financial Performance - The company's operating revenue for Q1 2019 was ¥932,134,661.99, a decrease of 1.05% compared to ¥942,006,366.62 in the same period last year[7] - Net profit attributable to shareholders was ¥26,899,235.72, down 47.62% from ¥51,357,567.04 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥24,026,919.39, a decline of 52.12% compared to ¥50,176,986.27 in the previous year[7] - Basic and diluted earnings per share were both ¥0.0144, down 47.64% from ¥0.0275 in the previous year[7] - The company reported a net loss of CNY 999,397,101.11 for the period, compared to a loss of CNY 979,173,497.37 in the previous period[40] - Total operating revenue for the current period is ¥932,134,661.99, a decrease of 1.0% from ¥942,006,366.62 in the previous period[41] - Net profit for the current period is ¥33,649,901.76, down 50.3% from ¥67,671,568.20 in the previous period[43] - Operating profit decreased to ¥59,716,502.89, a decline of 38.7% from ¥97,317,266.17 in the previous period[43] - The total comprehensive income for the current period is -¥4,964,883.14, compared to ¥66,879,664.14 in the previous period[44] Cash Flow and Liquidity - The net cash flow from operating activities was ¥101,220,316.55, a significant improvement from a negative cash flow of ¥8,666,208.61 in the same period last year[7] - Cash received from sales of goods and services was ¥845,637,677.40, a decrease from ¥914,404,711.96 in the previous period[50] - The net cash flow from financing activities was -¥143,248,277.39, reflecting increased debt repayments of ¥596,000,000.00 compared to ¥367,134,546.80 in the prior year[52] - The ending balance of cash and cash equivalents decreased to ¥237,711,312.75 from ¥413,957,872.27 year-over-year[52] - The company reported a significant increase in cash inflow from operating activities, rising to ¥106,006,083.55 from ¥3,136,216.23 in the previous year[55] - The cash outflow for operating activities was reduced to ¥15,511,273.10 from ¥97,926,590.60, indicating improved operational efficiency[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,841,307,875.56, an increase of 0.94% from ¥8,758,983,757.39 at the end of the previous year[7] - Total liabilities increased to CNY 5,988,622,609.80 from CNY 5,901,333,608.49, reflecting an increase of approximately 1.48%[34] - Current liabilities rose to CNY 3,027,142,930.49, up from CNY 2,964,779,474.64, indicating an increase of about 2.1%[34] - Long-term borrowings decreased to CNY 1,394,699,498.82 from CNY 1,588,827,002.10, a reduction of approximately 12.2%[34] - The total current assets were CNY 1,836,449,990.44[62] Shareholder Information - The top shareholder, Que Wenbin, holds 42.57% of the shares, amounting to 794,009,999 shares, which are pledged and frozen[10] - There were no significant changes in the number of shareholders or any repurchase transactions among the top shareholders during the reporting period[11] Non-Recurring Gains and Expenses - The company reported non-recurring gains totaling ¥2,872,316.33, primarily from non-current asset disposal and debt restructuring[8] - Research and development expenses skyrocketed by 5247.26% to ¥1.20 million, driven by increased investment in the Qili soft bag project[14] - Financial expenses rose by 81.68% to ¥45.36 million, due to increased loans and interest expenses[14] - Investment income increased by 266.77% to ¥7.19 million, resulting from the disposal of Guang'an Fuyuan and Guang'an Hengyuan hospitals[14] Regulatory Compliance and Commitments - The company reported a commitment to ensure the authenticity, accuracy, and completeness of information provided during the restructuring process, with strict adherence to commitments made in 2016[20] - The company has made long-term commitments regarding the authenticity of information provided by transaction parties during major asset restructuring, ensuring compliance with relevant regulations[20] - The actual controller of the company has committed to avoiding any competition with the company's business operations, ensuring that no competing activities will be undertaken by controlled entities[21] - The company has outlined measures to exit any potential competition that may arise from future business expansions, including ceasing operations or transferring competing businesses to unrelated third parties[21] - The company has confirmed that all commitments made are independently enforceable, and any violation resulting in losses will be fully compensated[21] - The company has reiterated its commitment to comply with relevant regulations regarding securities issuance and will not provide financial assistance or compensation to subscription targets[21] Other Financial Metrics - Cash and cash equivalents decreased by 31.55% to ¥237.71 million due to repayment of bank loans during the reporting period[14] - Other receivables increased by 40.03% to ¥129.77 million, attributed to new equity disposal collections[14] - Deferred tax assets decreased by 40.06% to ¥97.61 million, impacted by exchange rate fluctuations affecting the Australian subsidiary[14] - Prepayments increased by 66.38% to ¥89.35 million, reflecting a rise in hospital pre-collected inpatient fees[14] - Long-term payables surged by 350.10% to ¥358.16 million, indicating an increase in PRP long-term payables[14]

Business Model and Strategy - The company has transitioned from a single pharmaceutical manufacturing business to a dual-driven "big health" industry model, focusing on both medical services and pharmaceutical manufacturing [22]. - The company has outlined its future development strategy, which includes expanding its market presence and enhancing its product offerings [7]. - The company has emphasized the importance of risk awareness among investors regarding its forward-looking statements and operational plans [7]. - The company is focused on integrating traditional Chinese medicine with innovative biopharmaceutical research and market operations [41]. - The company aims to enhance its medical service quality and expand its market presence in response to the growing demand for healthcare services driven by urbanization and an aging population [98]. - The company plans to focus on major chronic diseases and high-end maternal and child health services, aligning with national health policies to improve traditional Chinese medicine and generic drug quality [98]. - The company will implement a new operational management structure to optimize resource allocation and enhance internal coordination [101]. - The company aims to establish a comprehensive health service network covering both urban and rural areas, particularly in elderly health and care services [106]. Financial Performance - The company reported a significant increase in user data, reflecting a growing customer base in its medical services sector [22]. - The company’s operating revenue for 2018 was ¥3,838,392,197.48, representing a 12.92% increase compared to the previous year [6]. - The net profit attributable to shareholders was -¥1,417,817,723.30, a decrease of 799.09% year-on-year [6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,395,854,132.33, a decline of 826.17% compared to the previous year [6]. - The total assets at the end of 2018 were ¥8,758,983,757.39, down 14.57% from the previous year [26]. - The net assets attributable to shareholders decreased to ¥2,711,131,540.28, a reduction of 35.27% year-on-year [26]. - The company reported a basic earnings per share of -¥0.7601, a decrease of 799.26% compared to the previous year [6]. - The total profit for the year was CNY -133,390.72 million, representing a year-on-year decline of 536.19% [61]. - The company reported a net loss of approximately ¥1.42 billion for 2018, compared to a net profit of ¥202.81 million in 2017 [117]. Investment and Acquisitions - The company acquired PRP Diagnostic Imaging Pty Ltd. for CNY 20.66 billion, representing 23.39% of the company's net assets [53]. - The company has invested in two industry merger funds, further expanding its market presence in the healthcare sector [39]. - The company established a wholly-owned subsidiary, Guang'an Hengyuan Hospital, in April 2018, expanding its consolidation scope [70]. - The company disposed of subsidiaries including Shanghai Shentuo Biotechnology and Dalian Dechang Pharmaceutical, reducing its consolidation scope [70]. - The company committed to a profit growth of no less than 10% for the acquired Guang'an Fuyuan Hospital, with a target net profit of RMB 1,089 million for 2018 [132]. Cash Flow and Dividends - The company plans not to distribute cash dividends or issue bonus shares, nor to increase capital using reserves [7]. - The cash dividend amount for 2018 was ¥0, representing 0.00% of the net profit attributable to ordinary shareholders [117]. - The company has ongoing funding requirements for various projects, including acquisitions and hospital construction, which influenced its decision on dividend distribution [113]. - The company plans to continue not distributing cash dividends or issuing bonus shares in the foreseeable future [118]. Operational Performance - The company operates a total of 1 tertiary hospital, 7 secondary or higher comprehensive hospitals, and 5 hospitals under construction, indicating a scale in its medical service industry [38]. - The company operates 15 hospitals with 8,700 open beds, serving over 3.5 million outpatient visits and 260,000 inpatient discharges annually, leveraging significant clinical resources for healthcare services [44]. - The company reported 3.5 million outpatient visits and 260,000 inpatient visits during the year, indicating a solid foundation in the healthcare service sector [61]. - The company launched the "Duyiwei" brand toothpaste series with pain relief, hemostatic, anti-inflammatory, and antibacterial functions, along with toothbrushes and hotel toothpaste products [40]. Market Trends and Demand - In 2017, China's total health expenditure reached 5.16 trillion yuan, growing by 11.34%, with an expected future growth rate of 10% [50]. - The medical service demand in China continues to grow, with a total of 7.54 billion medical visits recorded from January to November 2018, a year-on-year increase of 3.2% [50]. - The healthcare service market is rapidly developing, with private healthcare institutions showing particularly strong performance [48]. - Revenue from overseas markets surged by 94.57% to ¥956,499,460.32, representing 24.92% of total revenue [65]. Social Responsibility and Compliance - The company has actively fulfilled social responsibilities, investing approximately 1,027.26 million in poverty alleviation efforts, including 688.57 million in health-related assistance [192]. - The company has provided medical assistance to over 1,400 impoverished individuals with disabilities, with a total investment of approximately 154.06 million [192]. - The company has committed to continuing its targeted poverty alleviation plans in 2019, leveraging its industrial advantages [197]. - The company has maintained a 100% compliance rate in signing labor contracts and participating in social insurance for employees [186]. - The company has established a comprehensive internal management and control system to protect the rights of shareholders and creditors, ensuring transparency and compliance with disclosure obligations [186]. Risks and Challenges - The company has identified potential risks, including policy changes in healthcare reform, which may impact operations and will enhance its analysis and response strategies [107]. - The company’s financial performance has been impacted by asset impairment provisions and operational challenges in recent years [116]. - The company is currently appealing a judgment related to a performance commitment dispute, with a claim amount of CNY 91.03 million for unmet performance targets in 2017 [150]. Shareholder and Governance Issues - The company has not reported any changes in its controlling shareholders since its listing [22]. - The controlling shareholder, Mr. Que Wenbin, has 794,009,999 shares frozen, accounting for 42.57% of the total share capital [157]. - The company did not face any situations that could lead to suspension or termination of listing during the reporting period [146]. - The company has committed to measures to avoid competition with its own subsidiaries and related entities [122].

恒康医疗集团股份有限公司 2018 年第三季度报告全文 恒康医疗集团股份有限公司 2018 年第三季度报告 2018 年 10 月 1 恒康医疗集团股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王成、主管会计工作负责人王勇及会计机构负责人(会计主管人 员)王中华声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 9,736,876,426.07 | | 10,253,239,638.48 | -5.04% | | 归属于上市公司股东的净资产 | 3,799,089,81 ...

恒康医疗集团股份有限公司 2018 年半年度报告全文 恒康医疗集团股份有限公司 2018 年半年度报告 2018 年 08 月 1 恒康医疗集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人周先敏、主管会计工作负责人王勇及会计机构负责人(会计主管 人员)王中华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告所涉及的公司未来发展战略、业绩规划等前瞻性陈述，属于未 来经营计划性事项，能否实现取决于市场状况变化等多种因素，存在不确定性， 并不代表公司对未来年度的盈利预测，也不构成公司对投资者及相关人士的实 质性承诺。投资者及相关人士均应对此保持足够的风险认识，且应当理解计划、 预测与承诺之间的差异。敬请投资者注意投资风险！ 公司已在本报告中详细描述了可能存在的主要风险，请查阅本报告第四节 "经营情况讨论与分析"章节相应内容。 公司计划不派发现金红利，不送红股，不以公积金 ...

Financial Performance - The company's operating revenue for 2017 was CNY 3,399,324,143.50, representing a 56.27% increase compared to CNY 2,175,221,187.39 in 2016[17]. - The net profit attributable to shareholders decreased by 49.75% to CNY 202,809,263.86 from CNY 403,631,489.47 in the previous year[17]. - The total profit for the year was 305.81 million RMB, which is a decrease of 33.75% compared to the previous year[60]. - The basic earnings per share decreased by 49.18% to CNY 0.1087 from CNY 0.2139 in the previous year[17]. - The weighted average return on equity was 4.88%, down from 10.29% in 2016, reflecting a decline of 5.41%[18]. - The company reported a net profit attributable to ordinary shareholders of approximately CNY 202.81 million in 2017, with no cash dividends proposed for the year[137]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -204,818,621.09, an improvement of 70.63% from CNY -697,374,078.56 in 2016[17]. - The total assets at the end of 2017 reached CNY 10,253,239,638.48, a 71.32% increase from CNY 5,984,709,625.84 in 2016[18]. - The company achieved a revenue of 3,399.32 million RMB in 2017, representing a year-on-year growth of 56.27%[60]. - The company has seen a 204.37% year-on-year increase in construction in progress, attributed to new projects in oncology and health industries[47]. - The company’s intangible assets have increased by 79.35% year-on-year, mainly from the acquisition of PRP company[47]. Business Expansion and Strategy - The company has transitioned from a single pharmaceutical manufacturing business to a diversified operation including medical services, pharmaceuticals, cosmetics, and health products[15]. - The company aims to expand its medical service scale through both mergers and acquisitions and organic growth, enhancing its overall service level[36]. - The company is actively expanding its pharmaceutical, daily chemical, and health product business segments[38]. - The company plans to publicly issue corporate bonds totaling no more than 1.5 billion RMB to enhance financing channels and reduce costs[68]. - The company is collaborating with universities and large public hospitals to introduce advanced talent and technology[37]. Medical Services and Infrastructure - The company has established a complete medical industry chain, including health check-ups, diagnosis, treatment, and post-operative rehabilitation, through acquisitions and self-built hospitals[27]. - The company directly controls 8 hospitals and has 5 hospitals under construction, enhancing its medical service scale[29]. - The company has implemented a centralized procurement strategy to optimize costs and improve the quality of medical supplies across its hospitals[34]. - The company is actively developing independent imaging centers to enhance its medical imaging platform and improve service capabilities[65]. - The company is focusing on developing derivative products in its daily chemical and health product segments to enrich its product structure[123]. Risks and Challenges - The company has detailed potential risks in its report, emphasizing the need for investors to be aware of market uncertainties[5]. - The company recognizes potential policy risks related to healthcare reforms that could impact its operations and plans to adapt accordingly[126]. - The company has not distributed cash dividends in the past three years, despite positive net profits[137]. Community and Social Responsibility - The company invested approximately CNY 11.55 million in its poverty alleviation efforts, with CNY 7.89 million allocated to health poverty alleviation and CNY 2.43 million for basic security support[187]. - The company supported over 1,600 impoverished disabled individuals through its social poverty alleviation initiatives[187]. - The company’s health poverty alleviation efforts included community clinics and free medical screenings, addressing the issue of poverty caused by illness[187]. - The company actively engaged in community service through free medical consultations, improving its social responsibility profile[183]. Corporate Governance and Compliance - The company has committed to maintaining transparency and compliance with relevant laws and regulations regarding share changes and fundraising[141]. - The company has made commitments to avoid engaging in any competitive activities that may harm its interests or those of its shareholders[140]. - The company has established a financial assistance commitment to its subsidiary, ensuring that idle raised funds will not be used to supplement working capital[141]. - The company has maintained its auditor, Ruihua CPA, for nine consecutive years, with audit fees amounting to 1.49 million CNY[155].

恒康医疗集团股份有限公司 2018 年第一季度报告正文 证券代码：002219 证券简称：恒康医疗 公告编号：2018-046 恒康医疗集团股份有限公司 2018 年第一季度报告正文 1 恒康医疗集团股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周先敏、主管会计工作负责人王勇及会计机构负责人(会计主管 人员)王中华声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 942,006,366.62 | 488,768,340.81 | 92.73% | | 归属于上市公司股东的净利润（元） ...

恒康医疗集团股份有限公司 2017 年第三季度报告正文 证券代码：002219 证券简称：恒康医疗 公告编号：2017-116 恒康医疗集团股份有限公司 2017 年第三季度报告正文 1 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 恒康医疗集团股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周先敏、主管会计工作负责人王勇及会计机构负责人(会计主管 人员)王中华声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2017 年第三季度报告正文 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | --- | | 总资产（元） | 8,664,250,578.05 | 5,984,709,625.84 | | | 44. ...

恒康医疗集团股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 恒康医疗集团股份有限公司 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 2017 年半年度报告 公司负责人周先敏、主管会计工作负责人王勇及会计机构负责人(会计主管 人员)王中华声明：保证本半年度报告中财务报告的真实、准确、完整。 2017 年 08 月 所有董事均已出席了审议本报告的董事会会议。 1 恒康医疗集团股份有限公司 2017 年半年度报告全文 2 恒康医疗集团股份有限公司 2017 年半年度报告全文 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | 第三节 | 公司业务概要 9 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 22 | | 第六节 | 股份变动及股东情况 35 | | 第七节 | 优先股相关情况 38 | | 第八节 | 董事、监事、高级管理人员情况 39 | | 第九节 | 公司债相关情况 ...

恒康医疗集团股份有限公司 2017 年第一季度报告正文 证券代码：002219 证券简称：恒康医疗 公告编号：2017-043 恒康医疗集团股份有限公司 2017 年第一季度报告正文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人周先敏、主管会计工作负责人王勇及会计机构负责人(会计主管 人员)王中华声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2017 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 1 恒康医疗集团股份有限公司 2017 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 488,768,340.81 | 375,702,316.45 | 30.09% | | 归属于 ...